1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bayer And Morphosys Brush Off ADC Mesothelioma Failure

 
• By Alexandra Shimmings

A mid-stage trial of a Bayer/Morphosys antibody-drug conjugate for mesothelioma has failed, crossing one indication off the list of its potential uses, but development in other indications continues.

Anthophyllite asbestos
Asbestos In its raw form • Source: Shutterstock

A large Phase II trial of an antibody-drug conjugate anetumab ravtansine (BAY 949343) under development by Bayer AG and MorphoSys AG has failed to show any benefit in recurrent malignant pleural mesothelioma, but the companies are still hopeful of success in other indications.

The study, conducted by Bayer in 248 patients with recurrent malignant pleural mesothelioma whose disease had progressed after treatment with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D